Analyst Price Target is $13.50
▲ +431.50% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioVie in the last 3 months. The average price target is $13.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 431.50% upside from the last price of $2.54.
Current Consensus is
Buy
The current consensus among 2 contributing investment analysts is to buy stock in BioVie.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
Read More